Rosiglitazone is used to help control blood sugar levels in people with type 2 diabetes by making the body more sensitive to insulin.[2] Avandia is currently approved and in use across 31 indications[4].[1]
Avandia is one of 711 small molecule programs targeting Insulin resistance. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Competition
702 competitors in Breast Cancer
Avandia
Lexiscan
Voltaren
Zolymbus
Blenoxane
Methylthioninium Chloride
Sporanox
Tricor
Vfend
Neoadjuvant Treatment
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
May 25, 1999
AVANDIA
NDA NDA021071
Sources
Details